| 公布日 | 投资方 | 交易金额 | 融资轮次 | | --- | --- | --- | --- | | 2025-11-13 | 南山战新投 | 千万级人民币 | Pre-A+轮 | | 2025-11-04 | 创东方投资 | 未披露 | Pre-A轮 | | 2025-10-14 | HongShan红杉中国 | 数千万人民币 | 天使+ | | | 江西全控资本 | | | | 2023-11-30 | 仙瞳资本 | 数千万人民币 | 天使轮 | | | 力合科创 | | | | 2023-02-28 | 深圳津北投资合伙企业(有限合伙) | 数百万人民币 | 种子轮 | 证券之星消息，根据天眼查APP于11月13日公布的信息整理，深圳津渡生物医学科技有限公司Pre-A+轮 融资，融资额千万级人民币，参与投资的机构包括南山战新投。 数据来源：天眼查APP 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 津渡生科（OxTium Technology）致力于开发多模态医学诊断大模型，主要聚焦多组学分析（RNA组、 DNA组 ...

Core Viewpoint - The article emphasizes the integration of AI tools, particularly DeepSeek, in enhancing research methodologies in bioinformatics, specifically in the analysis of multi-omics data and the design of research projects [1][3][29]. Course Structure - The course includes practical sessions on AI-assisted design of research topics, focusing on multi-omics data analysis, including metabolomics, proteomics, and genomics [3][30]. - It covers the use of AI for efficient reading and summarizing of CNS literature, as well as the evaluation of innovative ideas and data analysis feasibility in bioinformatics [3][29]. AI Applications in Bioinformatics - AI is utilized for sample grouping, data filtering from public databases, and visualizing bioinformatics analysis results [4][19]. - The course includes modules on machine learning applications in metabolomics, proteomics, and transcriptomics, highlighting various algorithms and their implementations [33][40]. Research Methodologies - The curriculum emphasizes the importance of understanding and applying various statistical and machine learning methods for data analysis, including regression models and clustering techniques [44][40]. - It also includes practical coding sessions to replicate high-level research from CNS articles, enhancing hands-on experience [50][51]. Continuous Support and Learning - The program offers ongoing support and one-on-one guidance even after course completion, ensuring that participants can effectively apply their learning in real-world scenarios [22][24][50]. - The course is designed to be flexible, allowing participants to revisit materials and receive assistance as needed [22][26].

Group 1 - The company reported a significant increase in performance for H1 2025, with revenue reaching 307 million yuan, a year-on-year growth of 17.6%, and net profit attributable to shareholders increasing by 59.0% and 88.5% for the non-deduction and deduction cases respectively [1] - In Q2 2025, revenue was 151 million yuan, showing a year-on-year increase of 4.8%, while net profit attributable to shareholders was 63 million yuan and 59 million yuan, reflecting year-on-year growth of 44.5% and 71.4% respectively [1] - The company maintains its profit forecasts for 2025-2027, predicting net profits of 192 million, 230 million, and 276 million yuan, with corresponding EPS of 1.14, 1.37, and 1.64 yuan, indicating a PE ratio of 24.8, 20.7, and 17.2 times [1] Group 2 - The domestic market continues to benefit from the new national standards, driving growth in ARA and DHA, with expectations for continued revenue growth in H2 2025 [2] - The gross profit margin has significantly improved, with a year-on-year increase of 7.24 percentage points and a quarter-on-quarter increase of 1.87 percentage points, attributed to scale effects and reduced costs [2] - The net profit margin for Q2 2025 reached 41.76%, with a year-on-year increase of 11.46 percentage points, indicating strong profitability [2] Group 3 - The restructuring target, Ouyi Biological, has committed to a cumulative net profit of no less than 270 million yuan from 2025 to 2027, averaging 90 million yuan per year, indicating high growth potential [3] - Ouyi Biological is in the early stages of multi-omics analysis, with significant opportunities for overseas market expansion and technological application [3] - The completion of the asset restructuring is expected to enhance the company's foundational R&D capabilities and accelerate new product development [3]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company is expected to achieve a record high quarterly profit, maintaining an optimistic outlook for the second half of 2025 [4] - The company's revenue for H1 2025 reached 307 million yuan, a year-on-year increase of 17.6%, with net profit attributable to the parent company growing by 59.0% and 88.5% for the non-deduction and deduction cases respectively [4][5] - The acquisition of Ouyisheng Biological is anticipated to enhance the company's development potential, with a projected cumulative net profit of no less than 270 million yuan from 2025 to 2027 [7] Financial Performance - In Q2 2025, the company's revenue was 151 million yuan, a year-on-year increase of 4.8%, with net profit attributable to the parent company increasing by 44.5% and 71.4% for the non-deduction and deduction cases respectively [4][5] - The gross profit margin in Q2 2025 improved significantly, with a year-on-year increase of 7.24 percentage points, reaching 41.76% [6] - The company forecasts net profits of 192 million, 230 million, and 276 million yuan for 2025, 2026, and 2027 respectively, with corresponding EPS predictions of 1.14, 1.37, and 1.64 yuan [4][9] Market Outlook - The domestic market is benefiting from new national standards, driving growth in ARA and DHA products [5] - The company expects continued revenue growth in the domestic market for Q2 2025, while international market revenue may slightly decline due to high base effects [5] - The second half of 2025 is expected to bring additional growth opportunities in the health food sector, particularly for DHA products [5] Valuation Metrics - The current stock price corresponds to P/E ratios of 24.8, 20.7, and 17.2 for the years 2025, 2026, and 2027 respectively [4][9] - The company’s total market capitalization is 4.753 billion yuan, with a circulating market capitalization also at 4.753 billion yuan [1]